B., A.S., I.N.; Formal analysis: P.M. (Paola Mapelli
B., A.S., I.N.; Formal evaluation: P.M. (Paola Mapelli), S.G., P.S.; Information curation: P.M. (Paola Mapelli), S.G., A.M.S.G., G.B., V.C., E.P., P.M. (Patrizia Magnani), R.M., N.A., M.F., E.D.G.; Writing–original draft preparation: P.M. (Paola Mapelli), S.G., P.S., M.P.; Writing–review and editing: P.M. (Paola Mapelli), S.G., G.B., A.B., F.D.C., A.M.S.G., L.G., P.S., M.P.; Supervision: P.M. (Paola Mapelli), P.S., M.P. All authors have study and agreed to the published version from the manuscript. Funding: This study was funded by the Italian Association for Cancer Research (grant IG 2017 Id. 20571) and by the Italian Ministry of Wellness (PE-2016-02361273); EUDRACT quantity: 2018-001034-18. Signa PET/MRI program (GEMS, Wakesha, WI, USA) employed in the present work was bought with funding from the Italian Ministry of Health. Institutional Assessment Board Statement: This study was authorized by the Institutional Ethics Committee of IRCCS San Raffaele Scientific Institute (EudraCT: 2018-001034-18) and all patients gave written informed consent to participate in the study. Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Conflicts of Interest: The authors declare no conflict of interest. The funders had no part in the design and style with the study; in the collection, analyses, or interpretation of information; in the writing of your manuscript, or in the choice to publish the results.
diagnosticsArticleUrinary SARS-CoV-2 RNA Is an Indicator for the Tianeptine sodium salt web Progression and Prognosis of COVID-Lu Zhang 1, , Maoqing Tian 1, , Yuan Song 1 , Wei Liang 1 , Xiaogang Li 2 , Yongqing Tong 3, and Huiming Wang 1, Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan 430060, China; [email protected] (L.Z.); [email protected] (M.T.); [email protected] (Y.S.); [email protected] (W.L.) Division of Nephrology, Division of Medicine, Mayo Clinic, Rochester, MN 55905, USA; [email protected] Department of Laboratory Science, Renmin Hospital of Wuhan University, Wuhan 430060, China Correspondence: [email protected] (Y.T.); [email protected] (H.W.) These authors contributed equally for the report and share very first authorship.Citation: Zhang, L.; Tian, M.; Song, Y.; Liang, W.; Li, X.; Tong, Y.; Wang, H. Urinary SARS-CoV-2 RNA Is definitely an Indicator for the Progression and Prognosis of COVID-19. Diagnostics 2021, 11, 2089. https://doi.org/ 10.3390/diagnostics11112089 Academic Editor: Giulia Bivona Received: 23 September 2021 Accepted: 10 November 2021 Published: 12 NovemberAbstract: Background: We aimed to analyze clinical qualities and uncover prospective elements to predict poor prognosis in patients with coronavirus illness 2019 (COVID-19). Procedures: We analyzed the clinical characteristics and laboratory tests of COVID-19 sufferers and detected SARS-CoV-2 RNA in urine sediments collected from 53 COVID-19 sufferers enrolled in Renmin Hospital of Wuhan University from 31 January 2020 to 18 February 2020 with qRT-PCR D-Fructose-6-phosphate disodium salt Technical Information evaluation. Then, we classified these individuals depending on clinical circumstances (serious or non-severe syndrome) and urinary SARS-CoV-2 RNA (URNA – or URNA + ). Final results: We found that COVID-19 patients with severe syndrome (extreme patients) showed significantly greater optimistic price (11 of 23, 47.8 ) of urinary SARS-CoV-2 RNA than non-severe sufferers (4 of 30, 13.3 , p = 0.006). URNA + sufferers or serious URNA + subgroup exhibited greater prevalence of inflammation and immune discord, cardiovascular ailments, liver damage and renal.
